Although numbers were small, in this study we have reported a state of heightened immune ageing in the preclinical phase; with the IMM-AGE score higher in ACPA+ve patients with arthralgia that developed RA over a 24 month follow up period. This evidence concerns the gene PRTN3 and rheumatoid arthritis.